Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2001

View Archived Issues

INOmax approved in Europe for treating critically ill newborns

Neuroprotective activity of estrogens and SERMs examined at congress

Enrollment begins in new clinical trials of 7-day combination contraceptive patch

Bristol-Myers Squibb selects potential drug targets from Lexicon's LexVision database

Periostat tablets for periodontitis granted dental practitioners formulary status in the UK

Enrollment completed in novel trial for prevention of hypertension

Clinical program for Vitrix living dermal replacement begins

Product R enhances production and secretion of proinflammatory chemokines in human monocytes

Rituximab tested as a treatment for chronic ITP

Pfizer describes erythromycin A derivatives with antibacterial and antiprotozoal activity

New benzamidine derivatives with anticoagulant activity designed by Ajinomoto

Ajinomoto patents new series of factor VII inhibitors

New class of antibacterials reported by Ortho-McNeil

Venlafaxine ER shows good long-term results in GAD patients

First clinical trial of rhuCD40L in cancer patients completed

Approval of Remodulin recommended by the FDA for pulmonary arterial hypertension

FDA approves Natrecor for treatment of congestive heart failure

Zeltia and Ortho Biotech announce licensing agreement for ET-743

New antiarrhythmic agents identified at BMS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.